PE20230384A1 - Anticuerpos cd163 o proteinas de union - Google Patents
Anticuerpos cd163 o proteinas de unionInfo
- Publication number
- PE20230384A1 PE20230384A1 PE2022001329A PE2022001329A PE20230384A1 PE 20230384 A1 PE20230384 A1 PE 20230384A1 PE 2022001329 A PE2022001329 A PE 2022001329A PE 2022001329 A PE2022001329 A PE 2022001329A PE 20230384 A1 PE20230384 A1 PE 20230384A1
- Authority
- PE
- Peru
- Prior art keywords
- antibody
- porcine
- pigs
- ability
- antigen binding
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A61K2039/552—Veterinary vaccine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Virology (AREA)
- Animal Behavior & Ethology (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Communicable Diseases (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Referido a un anticuerpo monoclonal a CD 163 porcino, en donde dicho anticuerpo tiene la capacidad de unirse al dominio SRCR5 de CD163 porcino; en donde dicho anticuerpo tiene la capacidad de inhibir la infeccion por el virus del sindrome reproductivo y respiratorio porcino (PRRS) tipo 1 y/o tipo 2 en cerdo. Dicho anticuerpo comprende un dominio de union a antigeno que se une a CD163 porcino, comprendiendo dicho dominio de union a antigeno al menos una region variable de la cadena pesada que comprende tres regiones determinantes de la complementariedad (CDR), en donde dicha region variable de la cadena pesada comprende una CDR2 pesada variable (VH) que comprende la secuencia de aminoacidos XYAD o XYAE o XYAN, en la que X puede ser cualquier aminoacido, preferentemente, Y, L, P, N, F o R con mayor preferencia, Y,F, L, N o R, o Y, P o L, con la maxima preferencia, Y. Tambien se refiere a moleculas de acido nucleico que comprende secuencias de nucleotidos que codifican dicho anticuerpo, vectores de expresion, celulas huesped que comprenden dichos vectores de expresion, un metodo para producir dicho anticuerpo y una composicion farmaceuticamente aceptable que comprende dicho anticuerpo para su uso en el tratamiento o prevencion de la infeccion por el virus PRRS en cerdo.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1919294.7A GB201919294D0 (en) | 2019-12-24 | 2019-12-24 | Antibodies or binding proteins |
| PCT/GB2020/053370 WO2021130502A1 (en) | 2019-12-24 | 2020-12-24 | Cd163 antibodies or binding proteins |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20230384A1 true PE20230384A1 (es) | 2023-03-06 |
Family
ID=69322779
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2022001329A PE20230384A1 (es) | 2019-12-24 | 2020-12-24 | Anticuerpos cd163 o proteinas de union |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20230203185A1 (es) |
| EP (1) | EP4081542A1 (es) |
| JP (1) | JP7702952B2 (es) |
| KR (1) | KR20220119147A (es) |
| CN (1) | CN115151569A (es) |
| BR (1) | BR112022012362A2 (es) |
| CL (1) | CL2022001706A1 (es) |
| CO (1) | CO2022010294A2 (es) |
| DO (1) | DOP2022000136A (es) |
| GB (1) | GB201919294D0 (es) |
| MX (1) | MX2022007957A (es) |
| PE (1) | PE20230384A1 (es) |
| WO (1) | WO2021130502A1 (es) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7459354B2 (ja) * | 2022-07-08 | 2024-04-01 | ノヴォ ノルディスク アー／エス | ＦＶＩＩＩ（ａ）の代わりとなることができる非常に効力があるＩＳＶＤ化合物 |
| GB202214979D0 (en) * | 2022-10-11 | 2022-11-23 | Eco Animal Health Ltd | Binding protein |
| WO2024156888A1 (en) * | 2023-01-27 | 2024-08-02 | Vib Vzw | Cd163-binding conjugates |
| WO2025149667A1 (en) | 2024-01-12 | 2025-07-17 | Pheon Therapeutics Ltd | Antibody drug conjugates and uses thereof |
| CN119569865B (zh) * | 2024-12-20 | 2025-10-10 | 西北农林科技大学 | 一种防治猪繁殖与呼吸障碍综合征病毒感染的混合制剂及其制备方法和应用 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002076501A2 (en) * | 2001-03-26 | 2002-10-03 | Hemosol Inc. | Blood cell production via activation of the hemoglobin scavenger receptor |
| RU2357974C2 (ru) * | 2003-01-10 | 2009-06-10 | Аблинкс Н.В. | Терапевтические полипептиды, их гомологи, их фрагменты и их применение для модуляции агрегации, опосредованной тромбоцитами |
| US20160158368A1 (en) * | 2014-10-31 | 2016-06-09 | Therapure Biopharma Inc. | Methods and compositions for the treatment of histiocytosis |
| SI3331355T1 (sl) * | 2015-08-06 | 2024-10-30 | The Curators Of The University Of Missouri | Prašič, odporen na virus prašičjegaa reproduktivnega in respiratornega sindroma (PRRSV) in celice s spremenjenimi geni CD163 |
| US11160260B2 (en) * | 2018-04-17 | 2021-11-02 | The Curators Of The University Of Missouri | Methods for protecting porcine fetuses from infection with porcine reproductive and respiratory syndrome virus (PRRSV) |
-
2019
- 2019-12-24 GB GBGB1919294.7A patent/GB201919294D0/en not_active Ceased
-
2020
- 2020-12-24 EP EP20838276.2A patent/EP4081542A1/en active Pending
- 2020-12-24 JP JP2022539134A patent/JP7702952B2/ja active Active
- 2020-12-24 PE PE2022001329A patent/PE20230384A1/es unknown
- 2020-12-24 WO PCT/GB2020/053370 patent/WO2021130502A1/en not_active Ceased
- 2020-12-24 BR BR112022012362A patent/BR112022012362A2/pt unknown
- 2020-12-24 MX MX2022007957A patent/MX2022007957A/es unknown
- 2020-12-24 KR KR1020227025626A patent/KR20220119147A/ko not_active Ceased
- 2020-12-24 US US17/788,539 patent/US20230203185A1/en active Pending
- 2020-12-24 CN CN202080097372.4A patent/CN115151569A/zh active Pending
-
2022
- 2022-06-20 CL CL2022001706A patent/CL2022001706A1/es unknown
- 2022-06-23 DO DO2022000136A patent/DOP2022000136A/es unknown
- 2022-07-21 CO CONC2022/0010294A patent/CO2022010294A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP4081542A1 (en) | 2022-11-02 |
| BR112022012362A2 (pt) | 2022-09-06 |
| GB201919294D0 (en) | 2020-02-05 |
| CA3162664A1 (en) | 2021-07-01 |
| KR20220119147A (ko) | 2022-08-26 |
| WO2021130502A1 (en) | 2021-07-01 |
| CN115151569A (zh) | 2022-10-04 |
| MX2022007957A (es) | 2022-10-07 |
| JP7702952B2 (ja) | 2025-07-04 |
| JP2023508674A (ja) | 2023-03-03 |
| CO2022010294A2 (es) | 2022-10-31 |
| CL2022001706A1 (es) | 2023-05-26 |
| DOP2022000136A (es) | 2022-11-30 |
| US20230203185A1 (en) | 2023-06-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20230384A1 (es) | Anticuerpos cd163 o proteinas de union | |
| RU2462475C2 (ru) | Антитела против вируса гепатита с | |
| AR110755A1 (es) | Anticuerpos dirigidos a hueso | |
| AR106184A1 (es) | Proteínas de unión a pd-1 y sus métodos de uso | |
| RU2018133708A (ru) | Антитела, обладающие специфичностью к btla, и их использование | |
| FI3683235T3 (fi) | Anti-IL-33-vasta-aineita ja niiden käyttöjä | |
| PE20110225A1 (es) | Composiciones y metodos para anticuerpos que se dirigen a la proteina de complemento c5 | |
| PE20240802A1 (es) | Anticuerpos multiespecificos con especificidad para il-4r e il-31 | |
| JP2019505564A5 (es) | ||
| AR075504A1 (es) | Moleculas de anticuerpos que tienen especificidad para el ox40 humano | |
| AR084141A1 (es) | Anticuerpos neutralizadores anti-ccl20 | |
| AR075047A1 (es) | Metodos y composiciones en base a la proteina tipo 2 de la toxina shiga. polipeptido purificado. anticuerpo ant-stx2. kit. | |
| PE20220763A1 (es) | Materiales y metodos para modular la inmunidad mediada por celulas t | |
| JP2018520334A5 (es) | ||
| MX2023009022A (es) | Anticuerpos multiespecificos con especificidad para ror1 y cd3. | |
| CO2021014153A2 (es) | Anticuerpo monoclonal que se une específicamente a gitr | |
| PE20232050A1 (es) | Anticuerpos anti-cd19 y estructuras car-t | |
| BR112018072140A2 (pt) | anticorpos anti-basigin humanizados e uso dos mesmos | |
| PH12022552520A1 (en) | Antibodies binding siglec15 and uses thereof | |
| ZA202308896B (en) | Antibodies binding trop2 and uses thereof | |
| BR112022004603A2 (pt) | Anticorpo anti-cd371 ou um fragmento de ligação ao antígeno do mesmo, composição, imunoconjugado, molécula biespecífica, ácido nucleico, vetor de expressão, célula hospedeira, métodos e kit | |
| AR125488A1 (es) | Proteínas de unión biespecíficas de pd-1 y de tigit, y usos de las mismas | |
| PE20240589A1 (es) | ANTICUERPOS CD1a Y SU USO | |
| FI4031569T3 (fi) | Kantasolutekijän vasta-aineet ja niiden käyttömenetelmät | |
| WO2023202672A9 (en) | Antibodies targeting sirp-alpha and uses thereof |